Potential of Aqueous Humor as a Surrogate Tumor Biopsy for Retinoblastoma.
Jesse L Berry, Liya Xu, A Linn Murphree...
https://pubmed.ncbi.nlm.nih.gov/29049475Actively Recruiting
Age: 0Years - 18Years
All Genders
ID04959097
Retinoblastoma Patient Clinical Database and Tissue Repository
Led by Children's Hospital Los Angeles · Updated on 2026-04-22
800
Participants Needed
9
Research Sites
104 weeks
Total Duration
On this page
Sponsors
C
Children's Hospital Los Angeles
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Retinoblastoma (RB) is a primary eye cancer that develops in the retina of infants and toddlers. This research aims to systematically collect and study clinical data and biological samples from patients diagnosed with unilateral or bilateral retinoblastoma. The goal is to identify molecular markers in the eye's aqueous humor fluid, which may help predict treatment outcomes and improve personalized therapies. The study involves collecting and preserving biomaterials such as aqueous humor, blood, and saliva from patients with retinoblastoma. These samples will be analyzed to detect tumor-derived genetic information without the need for invasive tumor biopsies. Researchers will also record detailed clinical information about each patient's presentation, treatment, and outcomes. Participants will be followed through diagnosis and treatment, with outcomes monitored for at least 12 months and on average 24 months. The study will assess correlations between molecular biomarkers and eye salvage, gene mutations, and tumor characteristics. Data collection includes clinical assessments and laboratory analysis of the collected samples to better understand tumor behavior and treatment response over time.
CONDITIONS
Brief Title
Retinoblastoma Patient Clinical Database and Tissue Repository
Who Can Participate
Age: 0Years - 18Years
All Genders
Eligibility Criteria
You may qualify if you...
- All patients, age 0 days to 18 years, with a diagnosis of unilateral or bilateral retinoblastoma seen at Children's Hospital Los Angeles
You will not qualify if you...
- Patients referred for second opinions only and not treated at Children's Hospital Los Angeles for any reason
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Monitoring
Duration - Minimum of 12 months, average of 24 months
Participants who undergo routine care for retinoblastoma are observed while clinical data and biomaterials such as aqueous humor, blood, and saliva are collected and analyzed to study biomarkers and disease progression.
Visits scheduled according to routine clinical care, with additional biomaterial collection as appropriate
Trial Site Locations
Total: 9 locations
1
Phoenix Children's Hospital
Phoenix, Arizona, United States, 85016
Actively Recruiting
2
Children's Hospital Los Angeles
Los Angeles, California, United States, 90027
Actively Recruiting
3
Emory University Children's Healthcare of ATL
Atlanta, Georgia, United States, 30322
Actively Recruiting
4
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States, 60611
Actively Recruiting
5
Oregon Health & Science University: Casey Eye Institute
Portland, Oregon, United States, 97239
Actively Recruiting
6
Wills Eye Institute
Philadelphia, Pennsylvania, United States, 19107
Actively Recruiting
7
St. Jude Children's Research Hospital
Memphis, Tennessee, United States, 38105
Actively Recruiting
8
Seattle Children's Hospital; University of Washington
Seattle, Washington, United States, 98101
Actively Recruiting
9
The Hospital for Sick Children (Toronto SickKids)
Toronto, Ontario, Canada, M5G 2L3
Actively Recruiting
Loading map...
Research Team
J
Jesse L Berry, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Aqueous Humor Is Superior to Blood as a Liquid Biopsy for Retinoblastoma.
Jesse L Berry, Liya Xu, Ashley Polski...
https://pubmed.ncbi.nlm.nih.gov/31767439Genomic cfDNA Analysis of Aqueous Humor in Retinoblastoma Predicts Eye Salvage: The Surrogate Tumor Biopsy for Retinoblastoma.
Jesse L Berry, Liya Xu, Irsan Kooi...
https://pubmed.ncbi.nlm.nih.gov/30061186Chromosome 6p Amplification in Aqueous Humor Cell-Free DNA Is a Prognostic Biomarker for Retinoblastoma Ocular Survival.
Liya Xu, Ashley Polski, Rishvanth K Prabakar...
https://pubmed.ncbi.nlm.nih.gov/32434859Simultaneous identification of clinically relevant RB1 mutations and copy number alterations in aqueous humor of retinoblastoma eyes.
Liya Xu, Lishuang Shen, Ashley Polski...
https://pubmed.ncbi.nlm.nih.gov/32799607Cell-Free DNA Tumor Fraction in the Aqueous Humor Is Associated With Therapeutic Response in Retinoblastoma Patients.
Ashley Polski, Liya Xu, Rishvanth K Prabakar...
https://pubmed.ncbi.nlm.nih.gov/33062393Establishing the Clinical Utility of ctDNA Analysis for Diagnosis, Prognosis, and Treatment Monitoring of Retinoblastoma: The Aqueous Humor Liquid Biopsy.
Liya Xu, Mary E Kim, Ashley Polski...
https://pubmed.ncbi.nlm.nih.gov/33805776